438 Studies Now Enrolling
ICON3: A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
ICON3: A Phase 3 Study of Eltrombopag vs. Standard Therapy for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
| Sponsor: | Baylor College of Medicine |
| Enrolling: | Male and Female Patients |
| Study Length: | 1 Years |
| Clinic Visits: | 14 |
| IRB Number: | AAAS3726 |
| U.S. Govt. ID: | NCT03939637 |
| Contact: | Cindy Neunert, MD: 212-305-9770 / cn2401@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to investigate the safety and effectiveness of eltrombopag (investigational drug) in treating children and adolescents with newly-diagnosed immune thrombocytopenia (ITP), which is a rare blood disorder.
This study is closed
